Sonoma Pharmaceuticals (SNOA) EBITDA (2010 - 2025)

Sonoma Pharmaceuticals' EBITDA history runs 16 years deep, the most recent figure standing at -$645000.0 for Q4 2025.

• In Q4 2025, EBITDA rose 49.81% year-over-year to -$645000.0; the TTM figure through Dec 2025 stood at -$2.0 million (up 63.37% YoY), while the FY2025 annual figure was -$5.1 million, down 23.43% from the prior year.
• EBITDA was -$645000.0 for Q4 2025 at Sonoma Pharmaceuticals, down from -$329000.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$329000.0 in Q3 2025 to a low of -$4.0 million in Q1 2021.
• Historically, EBITDA has averaged -$1.2 million across 5 years, with a median of -$959500.0 in 2022.
• The sharpest annual moves came in 2021 and 2023: EBITDA tumbled 372.7% in 2021, then soared 79.52% in 2023.
• A 5-year view of EBITDA shows it stood at -$1.0 million in 2021, then tumbled by 68.88% to -$1.7 million in 2022, then soared by 66.61% to -$569000.0 in 2023, then plunged by 125.83% to -$1.3 million in 2024, then soared by 49.81% to -$645000.0 in 2025.
• The last three EBITDA figures came in at -$645000.0 (Q4 2025), -$329000.0 (Q3 2025), and -$435000.0 (Q2 2025), per Business Quant data.